Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways
Two genistein analogues (MD831 and MD833) have been synthesized and analyzed for their biological properties and their mechanism of action in comparison to genistein either in vitro or in intact cells. We showed that, in vitro, one of these compounds (MD831) inhibits the tyrosine kinase activity ass...
Saved in:
Published in | Biomedicine & pharmacotherapy Vol. 51; no. 6; pp. 286 - 294 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Paris
Elsevier SAS
1997
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Two genistein analogues (MD831 and MD833) have been synthesized and analyzed for their biological properties and their mechanism of action in comparison to genistein either in vitro or in intact cells. We showed that, in vitro, one of these compounds (MD831) inhibits the tyrosine kinase activity associated with the epidermal growth factor receptor (EGFR) as efficiently as genistein. However, treatment of A431 cells with these compounds did not result in any significant modification of EGFR tyrosine phosphorylation. Extracellular-signal regulated kinase (ERK) phosphorylation in cells stimulated by EGF was enhanced in the presence of MD831, whereas the other compounds, genistein and MD833, were able to activate the c-jun N-terminal kinase (JNK). This study showed that two structurally related compounds could elicit markedly different pharmacological effects on two signalling pathways, one involved in the mitogenic response and the other in the stress response. Such compounds may be useful to characterize signalling events involved in cell response to physiological stimuli. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0753-3322 1950-6007 |
DOI: | 10.1016/S0753-3322(97)83545-7 |